Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

M. Klanova, LH. Sehn, I. Bence-Bruckler, F. Cavallo, J. Jin, M. Martelli, D. Stewart, U. Vitolo, F. Zaja, Q. Zhang, F. Mattiello, G. Sellam, EA. Punnoose, E. Szafer-Glusman, CR. Bolen, MZ. Oestergaard, GR. Fingerle-Rowson, T. Nielsen, M. Trneny,

. 2019 ; 133 (9) : 919-926. [pub] 20190107

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045062

Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS-International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-expression profiling. BCL2 and MYC protein expression was analyzed by immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS relapse was assessed using a multivariate Cox regression model (data available in n = 1418, n = 933, and n = 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3-12.3; P = .02) and activated B-cell‒like (ABC) (HR, 5.2; 95% CI, 2.1-12.9; P = .0004) or unclassified COO subtypes (HR, 4.2; 95% CI, 1.5-11.7; P = .006) were independently associated with CNS relapse. BCL2/MYC dual-expression status did not impact CNS relapse risk. Three risk subgroups were identified based on the presence of high CNS-IPI score and/or ABC/unclassified COO (CNS-IPI-C model): low risk (no risk factors, n = 450 [48.2%]), intermediate risk (1 factor, n = 408 [43.7%]), and high risk (both factors, n = 75 [8.0%]). Two-year CNS relapse rates were 0.5%, 4.4%, and 15.2% in the respective risk subgroups. Combining high CNS-IPI and ABC/unclassified COO improved CNS relapse prediction and identified a patient subgroup at high risk for developing CNS relapse. The study was registered at www.clinicaltrials.gov as #NCT01287741.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045062
003      
CZ-PrNML
005      
20200113081642.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2018-07-862862 $2 doi
035    __
$a (PubMed)30617197
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klanova, Magdalena $u 1st Department of Medicine, Charles University General Hospital, Prague, Czech Republic. Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
245    10
$a Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL / $c M. Klanova, LH. Sehn, I. Bence-Bruckler, F. Cavallo, J. Jin, M. Martelli, D. Stewart, U. Vitolo, F. Zaja, Q. Zhang, F. Mattiello, G. Sellam, EA. Punnoose, E. Szafer-Glusman, CR. Bolen, MZ. Oestergaard, GR. Fingerle-Rowson, T. Nielsen, M. Trneny,
520    9_
$a Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS-International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-expression profiling. BCL2 and MYC protein expression was analyzed by immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS relapse was assessed using a multivariate Cox regression model (data available in n = 1418, n = 933, and n = 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3-12.3; P = .02) and activated B-cell‒like (ABC) (HR, 5.2; 95% CI, 2.1-12.9; P = .0004) or unclassified COO subtypes (HR, 4.2; 95% CI, 1.5-11.7; P = .006) were independently associated with CNS relapse. BCL2/MYC dual-expression status did not impact CNS relapse risk. Three risk subgroups were identified based on the presence of high CNS-IPI score and/or ABC/unclassified COO (CNS-IPI-C model): low risk (no risk factors, n = 450 [48.2%]), intermediate risk (1 factor, n = 408 [43.7%]), and high risk (both factors, n = 75 [8.0%]). Two-year CNS relapse rates were 0.5%, 4.4%, and 15.2% in the respective risk subgroups. Combining high CNS-IPI and ABC/unclassified COO improved CNS relapse prediction and identified a patient subgroup at high risk for developing CNS relapse. The study was registered at www.clinicaltrials.gov as #NCT01287741.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a nádory centrálního nervového systému $x farmakoterapie $x genetika $x sekundární $7 D016543
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $x patologie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a lokální recidiva nádoru $x diagnóza $x epidemiologie $x genetika $7 D009364
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $7 D019253
650    _2
$a protoonkogenní proteiny c-myc $x genetika $7 D016271
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sehn, Laurie H $u Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
700    1_
$a Bence-Bruckler, Isabelle $u The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
700    1_
$a Cavallo, Federica $u Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
700    1_
$a Jin, Jie $u Department of Hematology, The First Affiliated Hospital of Zheijiang University College of Medicine, Zheijiang, China.
700    1_
$a Martelli, Maurizio $u Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
700    1_
$a Stewart, Douglas $u Department of Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.
700    1_
$a Vitolo, Umberto $u AOU Citta' Della Salute e della Scienza, SC Ematologia, Turin, Italy.
700    1_
$a Zaja, Francesco $u SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.
700    1_
$a Zhang, Qingyuan $u Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
700    1_
$a Mattiello, Federico $u Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
700    1_
$a Sellam, Gila $u Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
700    1_
$a Punnoose, Elizabeth A $u Oncology Biomarker Development and.
700    1_
$a Szafer-Glusman, Edith $u Oncology Biomarker Development and.
700    1_
$a Bolen, Christopher R $u Bioinformatics, Genentech Inc., South San Francisco, CA; and.
700    1_
$a Oestergaard, Mikkel Z $u Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
700    1_
$a Fingerle-Rowson, Guenter R $u Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
700    1_
$a Nielsen, Tina $u Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
700    1_
$a Trneny, Marek $u 1st Department of Medicine, Charles University General Hospital, Prague, Czech Republic.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 133, č. 9 (2019), s. 919-926
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30617197 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082014 $b ABA008
999    __
$a ok $b bmc $g 1483331 $s 1083735
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 133 $c 9 $d 919-926 $e 20190107 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace